The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 30 September 2015 amounts to 271,822,806 shares, whereof 270,389,770 common shares and 1,433,036 class C shares, corresponding to in total 270,533,073.6 votes. The increase in the number of shares and votes results from an issue of 1,036,856 class C shares under Swedish Orphan Biovitrum's incentive program. The class C shares are intended to ensure fulfillment of commitments under incentive programs. The company holds 2,763,768 common shares and all 1,433,036 class C shares.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
For more information please contact
| Media relations | Investor relations |
| Oskar Bosson, Head of Communications | Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 | T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| oskar.bosson@sobi.com | jorgen.winroth@sobi.com |
The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 30 September 2015 at 08:00 CET.
HUG#1955119
